Network origin in Kristian Strømgaard first degree
Entity | Entity type | Industry | |
---|---|---|---|
Avilex Pharma ApS
Avilex Pharma ApS Pharmaceuticals: MajorHealth Technology Avilex Pharma ApS develops and produces drugs to treat brain damage with the uses of dimeric ligands. It also develops novel inhibitors to target a range of unmet medical needs. The firm uses dimeric ligands that targets intracellular with unprecedented potency. The company was founded by Kristian Strømgaard and Anders Bach on December 27, 2012 and is headquartered in Copenhagen, Denmark.
7
| Holding Company | Pharmaceuticals: Major | 7 |
Chart of Companies connected to the second degree
Multi-company connection
Companies connected to Kristian Strømgaard via their personal network
Company | Sector | Related people | Main position |
---|---|---|---|
University of Cambridge | College/University | Doctorate Degree Corporate Officer/Principal Masters Business Admin Graduate Degree | |
University College London | College/University | Doctorate Degree Undergraduate Degree | |
Minervax ApS
Minervax ApS Medical SpecialtiesHealth Technology Minervax ApS provides vaccine against streptococci. It utilizes fusion protein, which has proved to elicit good protective immunity. Its vaccine provides protective immunity against many clinically relevant GBS strains. The firm is engages in biotechnology, scientific and technical activities, and research and development. The company was founded in 2010 and is headquartered in Copenhagen, Denmark. | Medical Specialties | Chairman Director/Board Member | |
Novo Seeds
Novo Seeds Investment ManagersFinance Novo Seeds (Novo Seeds) is a venture capital operating division of Novo Nordisk Fonden. The firm was established in 2007, and is headquartered in Hellerup, Denmark. | Investment Managers | Director of Investments | |
OBSEVA SA | Pharmaceuticals: Major | Director/Board Member | |
Inthera Bioscience AG
Inthera Bioscience AG BiotechnologyHealth Technology Inthera Bioscience AG engages in the research in as well as development, production, and distribution of pharmaceutical, biological, and other products used in the fields of human and veterinary medicine. It also provides related consultancy services. The company was founded by Ulrich Kessler and Paramjit Singh Arora on September 20, 2013 and is headquartered in Zurich, Switzerland. | Biotechnology | Director/Board Member | |
Novo Ventures 1 A/S
Novo Ventures 1 A/S Investment ManagersFinance Novo Ventures (Novo Ventures) is a venture capital operating division of Novo Nordisk Fonden. It engages in investment activities. The firm was established in 1999, and is headquartered in Hellerup, Denmark. | Investment Managers | Corporate Officer/Principal | |
Glionova AB
Glionova AB Pharmaceuticals: MajorHealth Technology Glionova AB develops cancer treatment drugs. The firm is a drug discovery and development company. It offers GLN-1001 product. The company was founded by Lars G. J. Hammarström and Patrik Ernfors in 2014 and is headquartered in Stockholm, Sweden. | Pharmaceuticals: Major | Director/Board Member | |
Galecto Biotech ApS
Galecto Biotech ApS Pharmaceuticals: MajorHealth Technology Galecto Biotech ApS provides galectin modulators for the treatment of severe diseases, including fibrosis and cancer. Its products include galectin-3 inhibitors, fibrosis and literature. The company was founded by Tariq Sethi, Hans Thalsgard Schambye, Ulf Jorgen Nilsson, and Hakon Leffler in 2011 and is headquartered in Copenhagen, Denmark. | Pharmaceuticals: Major | Corporate Officer/Principal | |
Pcovery ApS
Pcovery ApS Pharmaceuticals: MajorHealth Technology Pcovery ApS develops drugs for treatment of invasive fungal infections. It discovers a new class of fungal therapy by targeting an essential and highly conserved component of the fungal cell membrane. The company was founded by Morten J. Buch-Pedersen, Michael Broberg Palmgren, Claus Olesen and Poul Nissen in 2009 and is headquartered in Copenhagen, Denmark. | Pharmaceuticals: Major | Director/Board Member | |
Affinicon ApS
Affinicon ApS Pharmaceuticals: MajorHealth Technology Affinicon ApS operates as a biotechnology company. It develops combinatory drugs for treatment of diseases such as inflammation, infections, and certain forms of cancer. The firm exploits a novel platform technology for targeted delivery of known drugs to macrophages. The company was founded by Niels Jonas Heilskov Graversen on July 4, 2013 and is headquartered in Aarhus, Denmark. | Pharmaceuticals: Major | Director/Board Member | |
University of Oxford | College/University | Undergraduate Degree | |
Cancer Research UK
Cancer Research UK Miscellaneous Commercial ServicesCommercial Services Cancer Research UK provides cancer research services. It supports and undertakes research on the biology and causes of cancer and develops anti-cancer drugs. The firm also provides general information about cancer and types of treatments and funds projects that help patients cope with the side effects of cancer and its treatment. Its institute also operates an online portal CancerHelp UK that provides patient information. The company was founded in 2001 and is headquartered in London, the United Kingdom. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
Apposite Capital LLP
Apposite Capital LLP Investment ManagersFinance Apposite Capital LLP (Apposite Capital) is a private equity arm of Mizuho Financial Group, Inc. founded in 2016 by David Porter. The firm is headquartered in London, United Kingdom. | Investment Managers | Private Equity Investor | |
ORPHAZYME A/S | Pharmaceuticals: Major | Director/Board Member | |
The Research Board, Inc.
The Research Board, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Gartner, Inc., The Research Board, Inc. is a company that provides information technology, research and consulting services. The company is based in New York, NY. The company was founded by Ernest M. von Simson, Naomi O. Seligman. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
SKF (U.K.) Ltd.
SKF (U.K.) Ltd. Metal FabricationProducer Manufacturing Part of SKF AB, SKF (U.K.) Ltd. is a British company that engages in manufacturing ball bearings. The company is based in Luton, UK. The company was founded in 1907 by Sven Wingqvist. | Metal Fabrication | Corporate Officer/Principal | |
Neuroscience Research Centre
Neuroscience Research Centre Miscellaneous Commercial ServicesCommercial Services Neuroscience Research Centre operates a science research center that supports and facilitates research in all areas of clinical neuroscience. The private company is based in Santa Barbara. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
Royal Pharmaceutical Society
Royal Pharmaceutical Society Miscellaneous Commercial ServicesCommercial Services Royal Pharmaceutical Society operates as a professional membership body for pharmacists and pharmacy. The private company is based in London, UK. and has subsidiaries in United Kingdom. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
Asceneuron SA
Asceneuron SA Pharmaceuticals: MajorHealth Technology Asceneuron SA operates as a biotechnology company. It develops therapeutics for orphan tauopathis and Alzheimer?s disease. The firm specializes in small molecule drug discovery for neurodegenerative diseases. The company was founded by Dirk Beher, Frank Murdoch Armstrong and Christoph Wiessner in October 2012 and is headquartered in Lausanne, Switzerland. | Pharmaceuticals: Major | Chairman | |
KAROLINSKA DEVELOPMENT AB | Financial Conglomerates | Director/Board Member | |
Academy of Medical Sciences
Academy of Medical Sciences Miscellaneous Commercial ServicesCommercial Services The Academy of Medical Sciences was founded in 1998 and provides biomedical and health research services. The non-profit company is based in London, UK. | Miscellaneous Commercial Services | Director/Board Member | |
Merck Sharp & Dohme Corp.
Merck Sharp & Dohme Corp. Pharmaceuticals: MajorHealth Technology Merck Sharp & Dohme Corp. engages in the research, development, and distribution of vaccines, prescription drugs, and animal health products. The company is headquartered in Whitehouse Station, NJ. | Pharmaceuticals: Major | Director/Board Member | |
British Pharmacological Society
British Pharmacological Society Investment Trusts/Mutual FundsMiscellaneous The British Pharmacological Society is a charity and membership organization that aims to promote and advance the field of pharmacology. The private company is based in London, UK. The British company leads the way in researching and applying pharmacology worldwide. The company was founded in 1931. Rachel Lambert-Forsyth has been the CEO of the company since 2020. | Investment Trusts/Mutual Funds | Chairman | |
OREXO AB | Pharmaceuticals: Major | Director/Board Member | |
Epsilon-3 Bio Ltd
Epsilon-3 Bio Ltd Pharmaceuticals: OtherHealth Technology Epsilon-3 Bio Ltd. develops compounds targeting the removal of cellular debris in chronic inflammatory and autoimmune disorders. The company was founded by Martin W. Edwards, Konstantinos Efthymiopoulos, David J. Grainger and Christian De La Tour on June 18, 2010 and is headquartered in Cambridge, the United Kingdom. | Pharmaceuticals: Other | Director/Board Member | |
Xention Pharma Ltd.
Xention Pharma Ltd. Pharmaceuticals: MajorHealth Technology Xention Pharma Ltd. develops and researches drugs. The firm develops novel therapies for the treatment of atrial fibrillation; modulators of IKur and IKACh for atrial fibrillation. The company was founded by John W. Word and is headquartered in Newmarket, the United kingdom. | Pharmaceuticals: Major | Founder | |
MERCK & CO., INC. | Pharmaceuticals: Major | Chairman | |
KalVista Pharmaceuticals Ltd.
KalVista Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology KalVista Pharmaceuticals Ltd. develops novel plasma kallikrein inhibitors. It also engages in the development of serine protease inhibitors and novel plasma kallikrein inhibitors represent a, approach to the treatment of DME, a leading cause of adult visual loss, plasma kallikrein inhibitors target a distinct molecular pathway and as such have the potential to offer those patients an effective treatment option. The firm has a clinical and advanced pre-clinical product pipeline targeting both intravitreal injection and oral administration, and its plasma kallikrein inhibitors can be applied to additional indications in ophthalmology. The company was founded by Lloyd Paul Aiello, Andrew Crockett, Robert Haigh and Edward P. Feener in 2011 and is headquartered in Porton Down, the United Kingdom. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
PetMedix Ltd.
PetMedix Ltd. BiotechnologyHealth Technology Petmedix Ltd. engages in developing therapeutics industry. It focuses on animal health by developing antibody therapeutics. The company was founded by Thomas Weaver and is headquartered in Cambridge, the United Kingdom. | Biotechnology | Director/Board Member | |
Microbiotica Ltd.
Microbiotica Ltd. BiotechnologyHealth Technology Microbiotica Ltd. performs research and experimental development on biotechnology. The company was founded by Michael Anthony Romanos, Trevor David Lawley and Gordon Dougan in December 2016 and is headquartered in Cambridge, the United Kingdom. | Biotechnology | Director/Board Member | |
Exvastat Ltd.
Exvastat Ltd. Pharmaceuticals: MajorHealth Technology Exvastat Ltd. operates as pharmaceutical company. The firm develops treatment for acute respiratory distress syndrome (ARDS) based on a repurposed drug which is marketed worldwide for other indications. The company was founded by David Cavalla , Charlotte Summers and Andrew McElroy in 2016 and is headquartered in Cambridge, the United Kingdom. | Pharmaceuticals: Major | Chairman | |
Congenica Ltd.
Congenica Ltd. BiotechnologyHealth Technology Congenica Ltd. develops genome-based discovery and diagnostic technologies. It uses Sapientia technology platform, which allows genome scale DNA sequence data to be presented within a clinically actionable diagnostic report. The company was founded by Matthew Hurles, Richard Durbin and Philip Beales in 2013 and is headquartered in Hinxton, the United Kingdom. | Biotechnology | Director/Board Member | |
CMR Surgical Ltd.
CMR Surgical Ltd. Medical SpecialtiesHealth Technology CMR Surgical Ltd. develops universal robotic system for minimal access surgery. The firm is presently evaluating the ability of the versius system to perform upper GI, gynaecological, colorectal and renal surgery in cadaveric trials. The company was founded by Martin Frost and Mark Slack in January 2014 and is headquartered in Cambridge, the United Kingdom. | Medical Specialties | Director/Board Member | |
Morphogen-IX Ltd.
Morphogen-IX Ltd. Miscellaneous Commercial ServicesCommercial Services Morphogen-IX Ltd. operates as a biotechnology company. It develops bone morphogenetic proteins as a novel therapy for the treatment of Pulmonary Arterial Hypertension. The company was founded in 2015 and is headquartered in Babraham, the United Kingdom. | Miscellaneous Commercial Services | Director/Board Member | |
Inivata Ltd.
Inivata Ltd. Packaged SoftwareTechnology Services Inivata Ltd. develops new clinical applications for ctDNA analysis. It is a clinical cancer genomics company harnessing the potential of circulating tumour DNA (ctDNA) analysis to improve cancer testing and treatment. The firm is focused on developing clinical applications of ctDNA through collaborations with clinical oncologists at prominent academic institutions, leading community treatment centres and innovative biopharmaceutical companies. The company was founded by James Brenton, Tim Forshew, Rosenfeld Nitzan and Davina Gale on July 23, 2014 and is headquartered in Cambridge, the United Kingdom. | Packaged Software | Director/Board Member | |
Royal College of Obstetricians & Gynaecologists | College/University | Corporate Officer/Principal | |
Abcodia Ltd.
Abcodia Ltd. BiotechnologyHealth Technology Abcodia Ltd. engages in the validation and discovery of molecular biomarkers. The firm works alongside University College London and in partnership with diagnostic, pharmaceutical and technology companies to exploit a prospective serum bank for the purpose of ethical biomarker validation and discovery. The company was founded in 2010 and is headquartered in London, the United Kingdom. | Biotechnology | Director/Board Member | |
Cambridge Innovation Capital Ltd
Cambridge Innovation Capital Ltd Investment ManagersFinance Cambridge Innovation Capital Ltd (Cambridge Innovation Capital) is a venture capital firm founded in 2013. The firm is headquartered in Cambridge, United Kingdom. | Investment Managers | Private Equity Investor | |
Sosei R&D Ltd.
Sosei R&D Ltd. Pharmaceuticals: MajorHealth Technology Sosei R&D Ltd. manufactures pharmaceutical products. It develops and commercializes product opportunities based upon clinical uses for known drugs and templates. The company was founded by Julian Gilbert and Robin Bannister in March, 2000 and is located in Saffron Walden, the United Kingdom. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
London Business School | College/University | Masters Business Admin | |
IO Biotech ApS
IO Biotech ApS BiotechnologyHealth Technology IO Biotech ApS operates as a clinical stage biotech company. It develops immunotherapy for cancer by targeting a mechanism used by tumour cells to evade immune responses. The company was founded by Mai-Britt Zocca, Mads Hald Andersen, Inge Marie Svane, Anders Ljungqvist and Per Thor Straten and is headquartered in Copenhagen, Denmark. | Biotechnology | Director/Board Member | |
Vantia Ltd.
Vantia Ltd. Miscellaneous Commercial ServicesCommercial Services Vantia Ltd. services to provide molecule agonists of vasopressin receptors. It offers healthcare improve clinical treatments through development and commercialization of innovative medicines. The company was founded by Robert Haigh and Chris Yea in 2008 and is headquartered in Southampton, the United Kingdom. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
Inversago Pharma, Inc.
Inversago Pharma, Inc. Pharmaceuticals: MajorHealth Technology Inversago Pharma, Inc. develops novel gastrointestinal drugs. The company was founded by Fran?ois Ravenelle in and is headquartered in Montreal, Canada. | Pharmaceuticals: Major | Director/Board Member | |
BIOINVENT INTERNATIONAL AB | Biotechnology | Director/Board Member | |
NBE-Therapeutics AG
NBE-Therapeutics AG BiotechnologyHealth Technology NBE-Therapeutics AG operates as biotechnology company. It develops next-generation ADCs improving treatment options for cancer patients. The company was founded by Ulf Grawunder in 2012 and is based in Basel, Swizerland. | Biotechnology | Director/Board Member | |
NodThera Ltd.
NodThera Ltd. BiotechnologyHealth Technology NodThera Ltd. researches and develops novel inhibitors of the NLRP3 inflammasome. The company is headquartered in Little Chesterford, the United Kingdom. | Biotechnology | Director/Board Member | |
Novo Holdings AS (Denmark)
Novo Holdings AS (Denmark) Financial ConglomeratesFinance Novo Holding A/S provides financial investments and manages the Novo Nordisk Foundation?s assets. It offers seed and venture capital to development stage companies and takes ownership positions in companies within life science and biotechnology. The company was founded on September 8, 1999 and is headquartered in Hellerup, Denmark. | Financial Conglomerates | Chief Investment Officer | |
Forbion Capital Partners Management Holding BV
Forbion Capital Partners Management Holding BV Investment ManagersFinance Forbion Capital Partners Management Holding BV (Forbion) is a Netherlands-based venture capital firm which was founded by Bart Bergstein. Headquartered in Naarden, the firm specializes in late-stage and early-stage clinical development programs to optimize the commercial potential of their investee company's technologies. | Investment Managers | Private Equity Investor | |
Numab Therapeutics AG
Numab Therapeutics AG Miscellaneous Commercial ServicesCommercial Services Numab Therapeutics AG is a biopharmaceutical company, which engages in the development of cancer immunotherapy. Its focuses on creating multi-specific antibodies that enable the pursuit of novel therapeutic strategies. The company was founded by Oliver Middendorp, David Urech, and Peter Lichtlen in 2011 and is headquartered in Wadenswil, Switzerland. | Miscellaneous Commercial Services | Director/Board Member |
Statistics
International
United Kingdom | 27 |
Denmark | 10 |
Switzerland | 6 |
Sweden | 5 |
United States | 5 |
Sectoral
Health Technology | 28 |
Commercial Services | 9 |
Finance | 8 |
Consumer Services | 6 |
Producer Manufacturing | 2 |
Operational
Director/Board Member | 61 |
Corporate Officer/Principal | 22 |
Chairman | 21 |
Chief Executive Officer | 7 |
Independent Dir/Board Member | 7 |
Most connected contacts
Insiders | |
---|---|
Nanna Liebach Lüneborg | 29 |
Ingelise Saunders | 28 |
Jonathan Treherne | 24 |
Ray Hill | 18 |
Robert Tansley | 18 |
Anders Bach | 1 |
Morten Graugaard Doessing | 1 |
- Stock Market
- Insiders
- Kristian Strømgaard
- Company connections